Private company trial initiations stand out in the latest week’s disclosures.

A just revealed phase 3 trial will apparently pit a fixed-dose combo head to head against Opdualag.

The biotech gives up on the exon 20 market, and says Tagrisso’s initial setting is no longer meaningful in the west.

Despite magrolimab’s latest flop, efforts to target CD47 continue.

For now, the group is sticking with what it knows ahead of a big year in lymphoma.